玉野井 冬彦

最終更新日時: 2019/06/28 10:37:47

印刷する

氏名(漢字/フリガナ/アルファベット表記)
玉野井 冬彦/タマノイ フユヒコ/Tamanoi, Fuyuhiko
所属部署・職名(部局/所属/講座等/職名)
高等研究院/物質-細胞統合システム拠点/特定教授
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
理学修士 東京大学
理学博士 名古屋大学
researchmap URL
https://researchmap.jp/7000019526
研究テーマ
(日本語)
ナノ粒子の構築と癌治療への応用
(英語)
Developing nanoparticles for their application for cancer therapy
研究概要
(日本語)
私達はナノ粒子を構築している。一つの特徴は多孔性の構造をしているので、表面積がひろいことである。そこに抗癌剤などを吸着することができる。抗癌剤を埋め込んだナノ粒子の効果を癌の動物モデルを使い検討している。
(英語)
We are developing mesoporous silica nanoparticles that for use in cancer therapy. Synthesis and characterization of these nanoparticles are ongoing. To examine the efficacy of anticancer drug loaded nanoparticles, we are using animal models.
研究分野(キーワード)
キーワード(日本語) キーワード(英語)
ナノ粒子 Nanoparticcles
癌治療 Cancer Therapy
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells, 8, 5 Cells, 8, 5 Cells, 8, 5 2019/05 公開
Doura Tomoshiro, Nishio Tadashi, Tamanoi Fuyuhiko, Nakamura Michihiro Doura Tomoshiro, Nishio Tadashi, Tamanoi Fuyuhiko, Nakamura Michihiro Doura Tomoshiro, Nishio Tadashi, Tamanoi Fuyuhiko, Nakamura Michihiro Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures JOURNAL OF MATERIALS RESEARCH, 34, 7, 1266-1278 JOURNAL OF MATERIALS RESEARCH, 34, 7, 1266-1278 JOURNAL OF MATERIALS RESEARCH, 34, 7, 1266-1278 2019/04/15 公開
Mekaru Harutaka, Yoshigoe Akitaka, Nakamura Michihiro, Doura Tomohiro, Tamanoi Fuyuhiko Mekaru Harutaka, Yoshigoe Akitaka, Nakamura Michihiro, Doura Tomohiro, Tamanoi Fuyuhiko Mekaru Harutaka, Yoshigoe Akitaka, Nakamura Michihiro, Doura Tomohiro, Tamanoi Fuyuhiko Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications ACS APPLIED NANO MATERIALS, 2, 1, 479-488 ACS APPLIED NANO MATERIALS, 2, 1, 479-488 ACS APPLIED NANO MATERIALS, 2, 1, 479-488 2019/01 公開
Doura T, Tamanoi F, Nakamura M Doura T, Tamanoi F, Nakamura M Doura T, Tamanoi F, Nakamura M Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. Journal of colloid and interface science, 526, 51-62 Journal of colloid and interface science, 526, 51-62 Journal of colloid and interface science, 526, 51-62 2018/09 公開
Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Scientific reports, 8, 1, 8524 Scientific reports, 8, 1, 8524 Scientific reports, 8, 1, 8524 2018/06 公開
Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Cytotechnology, 70, 2, 625-639 Cytotechnology, 70, 2, 625-639 Cytotechnology, 70, 2, 625-639 2018/04 公開
Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine : nanotechnology, biology, and medicine, 14, 4, 1381-1394 Nanomedicine : nanotechnology, biology, and medicine, 14, 4, 1381-1394 Nanomedicine : nanotechnology, biology, and medicine, 14, 4, 1381-1394 2018/04 公開
Heard JJ, Phung I, Potes MI, Tamanoi F Heard JJ, Phung I, Potes MI, Tamanoi F Heard JJ, Phung I, Potes MI, Tamanoi F An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC cancer, 18, 1, 69 BMC cancer, 18, 1, 69 BMC cancer, 18, 1, 69 2018/01 公開
Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. The Enzymes, 44, 103-116 The Enzymes, 44, 103-116 The Enzymes, 44, 103-116 2018 公開
Vallet-Regi M, Tamanoi F Vallet-Regi M, Tamanoi F Vallet-Regi M, Tamanoi F Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. The Enzymes, 43, 1-10 The Enzymes, 43, 1-10 The Enzymes, 43, 1-10 2018 公開
Tamanoi F Tamanoi F Tamanoi F Preface. Preface. Preface. The Enzymes, 43, xi The Enzymes, 43, xi The Enzymes, 43, xi 2018 公開
Le Hoang Doan T, Mai NXD, Matsumoto K, Tamanoi F Le Hoang Doan T, Mai NXD, Matsumoto K, Tamanoi F Le Hoang Doan T, Mai NXD, Matsumoto K, Tamanoi F Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. The Enzymes, 44, 61-82 The Enzymes, 44, 61-82 The Enzymes, 44, 61-82 2018 公開
Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorganic & medicinal chemistry letters, 27, 16, 3862-3866 Bioorganic & medicinal chemistry letters, 27, 16, 3862-3866 Bioorganic & medicinal chemistry letters, 27, 16, 3862-3866 2017/08 公開
Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine : nanotechnology, biology, and medicine, 13, 3, 965-976 Nanomedicine : nanotechnology, biology, and medicine, 13, 3, 965-976 Nanomedicine : nanotechnology, biology, and medicine, 13, 3, 965-976 2017/04 公開
Bathaie SZ, Ashrafi M, Azizian M, Tamanoi F Bathaie SZ, Ashrafi M, Azizian M, Tamanoi F Bathaie SZ, Ashrafi M, Azizian M, Tamanoi F Mevalonate Pathway and Human Cancers. Mevalonate Pathway and Human Cancers. Mevalonate Pathway and Human Cancers. Current molecular pharmacology, 10, 2, 77-85 Current molecular pharmacology, 10, 2, 77-85 Current molecular pharmacology, 10, 2, 77-85 2017 公開
Hu TY, Tamanoi F Hu TY, Tamanoi F Hu TY, Tamanoi F Preface. Preface. Preface. The Enzymes, 42, xi The Enzymes, 42, xi The Enzymes, 42, xi 2017 公開
Hayashi JY, Tamanoi F Hayashi JY, Tamanoi F Hayashi JY, Tamanoi F Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. The Enzymes, 42, 153-172 The Enzymes, 42, 153-172 The Enzymes, 42, 153-172 2017 公開
Croissant JG, Fatieiev Y, Julfakyan K, Lu J, Emwas AH, Anjum DH, Omar H, Tamanoi F, Zink JI, Khashab NM Croissant JG, Fatieiev Y, Julfakyan K, Lu J, Emwas AH, Anjum DH, Omar H, Tamanoi F, Zink JI, Khashab NM Croissant JG, Fatieiev Y, Julfakyan K, Lu J, Emwas AH, Anjum DH, Omar H, Tamanoi F, Zink JI, Khashab NM Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry (Weinheim an der Bergstrasse, Germany), 22, 42, 14806-14811 Chemistry (Weinheim an der Bergstrasse, Germany), 22, 42, 14806-14811 Chemistry (Weinheim an der Bergstrasse, Germany), 22, 42, 14806-14811 2016/10 公開
Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry (Weinheim an der Bergstrasse, Germany), 22, 28, 9607-9615 Chemistry (Weinheim an der Bergstrasse, Germany), 22, 28, 9607-9615 Chemistry (Weinheim an der Bergstrasse, Germany), 22, 28, 9607-9615 2016/07 公開
Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Journal of controlled release : official journal of the Controlled Release Society, 229, 183-191 Journal of controlled release : official journal of the Controlled Release Society, 229, 183-191 Journal of controlled release : official journal of the Controlled Release Society, 229, 183-191 2016/05 公開
Mekaru H, Lu J, Tamanoi F Mekaru H, Lu J, Tamanoi F Mekaru H, Lu J, Tamanoi F Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Advanced drug delivery reviews, 95, 40-49 Advanced drug delivery reviews, 95, 40-49 Advanced drug delivery reviews, 95, 40-49 2015/12 公開
Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine : nanotechnology, biology, and medicine, 11, 7, 1657-1666 Nanomedicine : nanotechnology, biology, and medicine, 11, 7, 1657-1666 Nanomedicine : nanotechnology, biology, and medicine, 11, 7, 1657-1666 2015/10 公開
Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F Significance of filamin A in mTORC2 function in glioblastoma. Significance of filamin A in mTORC2 function in glioblastoma. Significance of filamin A in mTORC2 function in glioblastoma. Molecular cancer, 14, 127 Molecular cancer, 14, 127 Molecular cancer, 14, 127 2015/07 公開
Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC cancer, 15, 381 BMC cancer, 15, 381 BMC cancer, 15, 381 2015/05 公開
Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity The Journal of biological chemistry, 290, 2, 1096-1105 The Journal of biological chemistry, 290, 2, 1096-1105 The Journal of biological chemistry, 290, 2, 1096-1105 2015/01 公開
Hwang AA, Lu J, Tamanoi F, Zink JI Hwang AA, Lu J, Tamanoi F, Zink JI Hwang AA, Lu J, Tamanoi F, Zink JI Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small (Weinheim an der Bergstrasse, Germany), 11, 3, 319-328 Small (Weinheim an der Bergstrasse, Germany), 11, 3, 319-328 Small (Weinheim an der Bergstrasse, Germany), 11, 3, 319-328 2015/01 公開
Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PloS one, 10, 9, e0137595 PloS one, 10, 9, e0137595 PloS one, 10, 9, e0137595 2015 公開
Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry (Weinheim an der Bergstrasse, Germany), 20, 30, 9372-9380 Chemistry (Weinheim an der Bergstrasse, Germany), 20, 30, 9372-9380 Chemistry (Weinheim an der Bergstrasse, Germany), 20, 30, 9372-9380 2014/07 公開
Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI Two-photon-triggered drug delivery via fluorescent nanovalves. Two-photon-triggered drug delivery via fluorescent nanovalves. Two-photon-triggered drug delivery via fluorescent nanovalves. Small (Weinheim an der Bergstrasse, Germany), 10, 9, 1752-1755 Small (Weinheim an der Bergstrasse, Germany), 10, 9, 1752-1755 Small (Weinheim an der Bergstrasse, Germany), 10, 9, 1752-1755 2014/05 公開
Nakashima A, Kamada S, Tamanoi F, Kikkawa U Nakashima A, Kamada S, Tamanoi F, Kikkawa U Nakashima A, Kamada S, Tamanoi F, Kikkawa U Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biology open, 3, 6, 542-552 Biology open, 3, 6, 542-552 Biology open, 3, 6, 542-552 2014/05 公開
Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. The Journal of biological chemistry, 289, 8, 4723-4734 The Journal of biological chemistry, 289, 8, 4723-4734 The Journal of biological chemistry, 289, 8, 4723-4734 2014/02 公開
Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angewandte Chemie (International ed. in English), 52, 51, 13813-13817 Angewandte Chemie (International ed. in English), 52, 51, 13813-13817 Angewandte Chemie (International ed. in English), 52, 51, 13813-13817 2013/12 公開
Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer discovery, 3, 5, 534-547 Cancer discovery, 3, 5, 534-547 Cancer discovery, 3, 5, 534-547 2013/05 公開
Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC cancer, 13, 198 BMC cancer, 13, 198 BMC cancer, 13, 198 2013/04 公開
Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small (Weinheim an der Bergstrasse, Germany), 9, 5, 697-704 Small (Weinheim an der Bergstrasse, Germany), 9, 5, 697-704 Small (Weinheim an der Bergstrasse, Germany), 9, 5, 697-704 2013/03 公開
Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. Journal of cell science, 125, Pt 23, 5840-5849 Journal of cell science, 125, Pt 23, 5840-5849 Journal of cell science, 125, Pt 23, 5840-5849 2012/12 公開
Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale, 4, 11, 3482-3489 Nanoscale, 4, 11, 3482-3489 Nanoscale, 4, 11, 3482-3489 2012/06 公開
Yanes RE, Tamanoi F Yanes RE, Tamanoi F Yanes RE, Tamanoi F Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic delivery, 3, 3, 389-404 Therapeutic delivery, 3, 3, 389-404 Therapeutic delivery, 3, 3, 389-404 2012/03 公開
Lu J, Li Z, Zink JI, Tamanoi F Lu J, Li Z, Zink JI, Tamanoi F Lu J, Li Z, Zink JI, Tamanoi F In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine : nanotechnology, biology, and medicine, 8, 2, 212-220 Nanomedicine : nanotechnology, biology, and medicine, 8, 2, 212-220 Nanomedicine : nanotechnology, biology, and medicine, 8, 2, 212-220 2012/02 公開
Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PloS one, 7, 7, e42012 PloS one, 7, 7, e42012 PloS one, 7, 7, e42012 2012 公開
Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small (Weinheim an der Bergstrasse, Germany), 7, 13, 1816-1826 Small (Weinheim an der Bergstrasse, Germany), 7, 13, 1816-1826 Small (Weinheim an der Bergstrasse, Germany), 7, 13, 1816-1826 2011/07 公開
Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI pH-Operated mechanized porous silicon nanoparticles. pH-Operated mechanized porous silicon nanoparticles. pH-Operated mechanized porous silicon nanoparticles. Journal of the American Chemical Society, 133, 23, 8798-8801 Journal of the American Chemical Society, 133, 23, 8798-8801 Journal of the American Chemical Society, 133, 23, 8798-8801 2011/06 公開
Tamanoi F Tamanoi F Tamanoi F Ras signaling in yeast. Ras signaling in yeast. Ras signaling in yeast. Genes & cancer, 2, 3, 210-215 Genes & cancer, 2, 3, 210-215 Genes & cancer, 2, 3, 210-215 2011/03 公開
Hardt M, Chantaravisoot N, Tamanoi F Hardt M, Chantaravisoot N, Tamanoi F Hardt M, Chantaravisoot N, Tamanoi F Activating mutations of TOR (target of rapamycin). Activating mutations of TOR (target of rapamycin). Activating mutations of TOR (target of rapamycin). Genes to cells : devoted to molecular & cellular mechanisms, 16, 2, 141-151 Genes to cells : devoted to molecular & cellular mechanisms, 16, 2, 141-151 Genes to cells : devoted to molecular & cellular mechanisms, 16, 2, 141-151 2011/02 公開
Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PloS one, 6, 10, e26135 PloS one, 6, 10, e26135 PloS one, 6, 10, e26135 2011 公開
Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Journal of the American Chemical Society, 132, 36, 12690-12697 Journal of the American Chemical Society, 132, 36, 12690-12697 Journal of the American Chemical Society, 132, 36, 12690-12697 2010/09 公開
Lu J, Liong M, Li Z, Zink JI, Tamanoi F Lu J, Liong M, Li Z, Zink JI, Tamanoi F Lu J, Liong M, Li Z, Zink JI, Tamanoi F Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small (Weinheim an der Bergstrasse, Germany), 6, 16, 1794-1805 Small (Weinheim an der Bergstrasse, Germany), 6, 16, 1794-1805 Small (Weinheim an der Bergstrasse, Germany), 6, 16, 1794-1805 2010/08 公開
Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Proceedings of the National Academy of Sciences of the United States of America, 107, 25, 11234-11239 Proceedings of the National Academy of Sciences of the United States of America, 107, 25, 11234-11239 Proceedings of the National Academy of Sciences of the United States of America, 107, 25, 11234-11239 2010/06 公開
Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small (Weinheim an der Bergstrasse, Germany), 6, 11, 1185-1190 Small (Weinheim an der Bergstrasse, Germany), 6, 11, 1185-1190 Small (Weinheim an der Bergstrasse, Germany), 6, 11, 1185-1190 2010/06 公開
Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer Oncogene, 29, 2746-2752 Oncogene, 29, 2746-2752 , 29, 2746-2752 2010/05 公開
Nakashima A, Sato T, Tamanoi F Nakashima A, Sato T, Tamanoi F Nakashima A, Sato T, Tamanoi F Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Journal of cell science, 123, Pt 5, 777-786 Journal of cell science, 123, Pt 5, 777-786 Journal of cell science, 123, Pt 5, 777-786 2010/03 公開
Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, DER CJ Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, DER CJ Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling Differential Requirement of CAAX-mediated Posttranslational Processing for Rheb Localization and Signaling Oncogene, 29, 3, 380-391 Oncogene, 29, 3, 380-391 Oncogene, 29, 3, 380-391 2010/01 公開
Sato T, Nakashima A, Tamanoi F Sato T, Nakashima A, Tamanoi F Sato T, Nakashima A, Tamanoi F [Rheb-mTOR signaling pathway involved in tumor formation]. [Rheb-mTOR signaling pathway involved in tumor formation]. [Rheb-mTOR signaling pathway involved in tumor formation]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 55, 1, 11-17 Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 55, 1, 11-17 Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 55, 1, 11-17 2010/01 公開
Parmar N, Tamanoi F Parmar N, Tamanoi F Parmar N, Tamanoi F Rheb G-Proteins and the Activation of mTORC1. Rheb G-Proteins and the Activation of mTORC1. Rheb G-Proteins and the Activation of mTORC1. The Enzymes, 27, 39-56 The Enzymes, 27, 39-56 The Enzymes, 27, 39-56 2010 公開
Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F A novel approach to tag and identify geranylgeranylated proteins. A novel approach to tag and identify geranylgeranylated proteins. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis, 30, 20, 3598-3606 Electrophoresis, 30, 20, 3598-3606 Electrophoresis, 30, 20, 3598-3606 2009/10 公開
Sato T, Nakashima A, Guo L, Tamanoi F Sato T, Nakashima A, Guo L, Tamanoi F Sato T, Nakashima A, Guo L, Tamanoi F Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. The Journal of biological chemistry, 284, 19, 12783-12791 The Journal of biological chemistry, 284, 19, 12783-12791 The Journal of biological chemistry, 284, 19, 12783-12791 2009/05 公開
Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular cancer therapeutics, 8, 5, 1218-1226 Molecular cancer therapeutics, 8, 5, 1218-1226 Molecular cancer therapeutics, 8, 5, 1218-1226 2009/05 公開
Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, Tamanoi F, Zink JI Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, Tamanoi F, Zink JI Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, Tamanoi F, Zink JI Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Journal of the American Ceramic Society. American Ceramic Society, 92, s1, s2-s10 Journal of the American Ceramic Society. American Ceramic Society, 92, s1, s2-s10 Journal of the American Ceramic Society. American Ceramic Society, 92, s1, s2-s10 2009/01 公開
Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer research, 68, 16, 6496-6506 Cancer research, 68, 16, 6496-6506 Cancer research, 68, 16, 6496-6506 2008/08 公開
Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS nano, 2, 5, 889-896 ACS nano, 2, 5, 889-896 ACS nano, 2, 5, 889-896 2008/05 公開
Lu J, Choi E, Tamanoi F, Zink JI Lu J, Choi E, Tamanoi F, Zink JI Lu J, Choi E, Tamanoi F, Zink JI Light-activated nanoimpeller-controlled drug release in cancer cells. Light-activated nanoimpeller-controlled drug release in cancer cells. Light-activated nanoimpeller-controlled drug release in cancer cells. Small (Weinheim an der Bergstrasse, Germany), 4, 4, 421-426 Small (Weinheim an der Bergstrasse, Germany), 4, 4, 421-426 Small (Weinheim an der Bergstrasse, Germany), 4, 4, 421-426 2008/04 公開
Lu J, Liong M, Zink JI, Tamanoi F Lu J, Liong M, Zink JI, Tamanoi F Lu J, Liong M, Zink JI, Tamanoi F Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small (Weinheim an der Bergstrasse, Germany), 3, 8, 1341-1346 Small (Weinheim an der Bergstrasse, Germany), 3, 8, 1341-1346 Small (Weinheim an der Bergstrasse, Germany), 3, 8, 1341-1346 2007/08 公開
Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology : the journal at the intersection of nanotechnology, molecular biology, and biomedical sciences, 3, 2, 89-95 Nanobiotechnology : the journal at the intersection of nanotechnology, molecular biology, and biomedical sciences, 3, 2, 89-95 Nanobiotechnology : the journal at the intersection of nanotechnology, molecular biology, and biomedical sciences, 3, 2, 89-95 2007/05 公開

  • <<
  • >>
  • 表示
タイトル言語:
外部資金:競争的資金・科学研究費補助金
種別 代表/分担 テーマ(日本語) テーマ(英語) 期間
国際共同研究加速基金(帰国発展研究) 代表 新規のホウ素含有ナノ粒子の構築とBNCTへの応用 (平成29年度分) 2017/04/01〜2018/03/31
国際共同研究加速基金(帰国発展研究) 代表 新規のホウ素含有ナノ粒子の構築とBNCTへの応用 (平成30年度分) 2018/04/01〜2019/03/31